Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy

Inclusion criteria:

• Type 2 diabetes mellitus patients, as defined by World Health Organization (WHO),diagnosed for at least 1 year at the time of screening visit who are under premixinsulin therapy, with or without oral anti-diabetic drug (OAD)

• Signed written informed consent

Exclusion criteria:

• HbA1c <7% or HbA1c >10% at screening

• No self-monitoring of blood glucose within 3 months prior to screening visit

• Premix insulin treatment for less than 3 months. Insulins other than premix insulintreatment within 3 months prior to screening visit

• In case of treatment with OAD, treatment with a stable OAD dose and regimen for lessthan 3 months prior to screening visit The above information is not intended to contain all considerations relevant to a patient'spotential participation in a clinical trial.